Global Insulin Glargine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Insulin Glargine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Insulin Glargine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Insulin Glargine market is projected to reach US$ 8856.1 million in 2034, increasing from US$ 6708 million in 2022, with the CAGR of 4.0% during the period of 2024 to 2034. Demand from Treat Type2 Diabetes and Treat Type1 Diabetes are the major drivers for the industry.
Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Insulin Glargine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi-Aventis
Ganlee
Biocon
Segment by Type
Single Dose Vial
Pre-filled Syringe
Treat Type2 Diabetes
Treat Type1 Diabetes
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Insulin Glargine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Insulin Glargine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Insulin Glargine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Insulin Glargine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Insulin Glargine introduction, etc. Insulin Glargine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Insulin Glargine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Insulin Glargine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Insulin Glargine market is projected to reach US$ 8856.1 million in 2034, increasing from US$ 6708 million in 2022, with the CAGR of 4.0% during the period of 2024 to 2034. Demand from Treat Type2 Diabetes and Treat Type1 Diabetes are the major drivers for the industry.
Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Insulin Glargine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi-Aventis
Ganlee
Biocon
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
Treat Type2 Diabetes
Treat Type1 Diabetes
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Insulin Glargine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Insulin Glargine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Insulin Glargine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Insulin Glargine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Insulin Glargine introduction, etc. Insulin Glargine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Insulin Glargine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices